ViroMed’s myocardial infarction therapy cleared for phase 2 trial

16:13
S. Korea not to attend Sado mine memorial: foreign ministry
16:01
Gyeongju blends old with new
16:01
[What to Play] Cozy songs to warm you up
16:01
[Weekender] Korea's traditional sauce culture gains global recognition
16:01
Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
16:01
At Gwangcheonok, try North Korean-style sundae gukbap
16:01
Over 80,000 malicious calls made to Seoul call center since 2020
12:52
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
11:45
BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
21:05
What you need to know about Adani's US bribery indictment

ViroMed’s myocardial infarction therapy cleared for phase 2 trial

Aug. 1, 2016 - 14:07 By 황유미

[DISCLOSURE] ViroMed (084990) announced on Aug. 1 that its VM202RY has been approved to initiate phase 2 of its clinical trials. VM202RY is a medicine for acute myocardial infarction by directly injecting into the cardiac muscles of the coronary artery territory.

황유미